BACKGROUND: The long-term impact of allogeneic hematopoietic stem cell transplantation (HSCT) on human immunodeficiency virus type 1 (HIV-1) reservoirs in patients receiving combination antiretroviral therapy (cART) is largely unknown. METHODS: We studied the effects of a reduced-intensity conditioning allogeneic HSCT from donors with wild-type-CCR5(+) cells on HIV-1 peripheral blood reservoirs in 2 patients heterozygous for the ccr5Δ32 mutation. In-depth analyses of the HIV-1 reservoir size in peripheral blood, coreceptor use, and specific antibody responses were performed on samples obtained before and up to 3.5 years after HSCT receipt. RESULTS: Although HIV-1 DNA was readily detected in peripheral blood mononuclear cells (PBMCs) before and 2-3 months after HSCT receipt, HIV-1 DNA and RNA were undetectable in PBMCs, CD4(+) T cells, or plasma up to 21 and 42 months after HSCT. The loss of detectable HIV-1 correlated temporally with full donor chimerism, development of graft-versus-host disease, and decreases in HIV-specific antibody levels. CONCLUSIONS: The ability of donor cells to engraft without evidence of ongoing HIV-1 infection suggests that HIV-1 replication may be fully suppressed during cART and does not contribute to maintenance of viral reservoirs in peripheral blood in our patients. HSCTs with wild-type-CCR5(+) donor cells can lead to a sustained reduction in the size of the peripheral reservoir of HIV-1.
BACKGROUND: The long-term impact of allogeneic hematopoietic stem cell transplantation (HSCT) on human immunodeficiency virus type 1 (HIV-1) reservoirs in patients receiving combination antiretroviral therapy (cART) is largely unknown. METHODS: We studied the effects of a reduced-intensity conditioning allogeneic HSCT from donors with wild-type-CCR5(+) cells on HIV-1 peripheral blood reservoirs in 2 patients heterozygous for the ccr5Δ32 mutation. In-depth analyses of the HIV-1 reservoir size in peripheral blood, coreceptor use, and specific antibody responses were performed on samples obtained before and up to 3.5 years after HSCT receipt. RESULTS: Although HIV-1 DNA was readily detected in peripheral blood mononuclear cells (PBMCs) before and 2-3 months after HSCT receipt, HIV-1 DNA and RNA were undetectable in PBMCs, CD4(+) T cells, or plasma up to 21 and 42 months after HSCT. The loss of detectable HIV-1 correlated temporally with full donor chimerism, development of graft-versus-host disease, and decreases in HIV-specific antibody levels. CONCLUSIONS: The ability of donor cells to engraft without evidence of ongoing HIV-1 infection suggests that HIV-1 replication may be fully suppressed during cART and does not contribute to maintenance of viral reservoirs in peripheral blood in our patients. HSCTs with wild-type-CCR5(+) donor cells can lead to a sustained reduction in the size of the peripheral reservoir of HIV-1.
Authors: Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano Journal: Nat Med Date: 2003-05-18 Impact factor: 53.440
Authors: Y Huang; W A Paxton; S M Wolinsky; A U Neumann; L Zhang; T He; S Kang; D Ceradini; Z Jin; K Yazdanbakhsh; K Kunstman; D Erickson; E Dragon; N R Landau; J Phair; D D Ho; R A Koup Journal: Nat Med Date: 1996-11 Impact factor: 53.440
Authors: A M de Roda Husman; M Koot; M Cornelissen; I P Keet; M Brouwer; S M Broersen; M Bakker; M T Roos; M Prins; F de Wolf; R A Coutinho; F Miedema; J Goudsmit; H Schuitemaker Journal: Ann Intern Med Date: 1997-11-15 Impact factor: 25.391
Authors: H K Holland; R Saral; J J Rossi; A D Donnenberg; W H Burns; W E Beschorner; H Farzadegan; R J Jones; G V Quinnan; G B Vogelsang Journal: Ann Intern Med Date: 1989-12-15 Impact factor: 25.391
Authors: Anthony R Cillo; Amrita Krishnan; Ronald T Mitsuyasu; Deborah K McMahon; Shirley Li; John J Rossi; John A Zaia; John W Mellors Journal: J Acquir Immune Defic Syndr Date: 2013-08-01 Impact factor: 3.731
Authors: M Dean; M Carrington; C Winkler; G A Huttley; M W Smith; R Allikmets; J J Goedert; S P Buchbinder; E Vittinghoff; E Gomperts; S Donfield; D Vlahov; R Kaslow; A Saah; C Rinaldo; R Detels; S J O'Brien Journal: Science Date: 1996-09-27 Impact factor: 47.728
Authors: L Contu; G La Nasa; M Arras; A Pizzati; A Vacca; C Carcassi; A Ledda; R Boero; S Orrù; A Pintus Journal: Bone Marrow Transplant Date: 1993-12 Impact factor: 5.483
Authors: C Leboeuf; J Roser-Schilder; M Lambotin; S Durand; T Wu; C Fauvelle; B Su; E Bôle-Richard; M Deschamps; C Ferrand; P Tiberghien; P Pessaux; T F Baumert; E Robinet Journal: Gene Ther Date: 2014-11-13 Impact factor: 5.250
Authors: Hiromi Imamichi; Robin L Dewar; Joseph W Adelsberger; Catherine A Rehm; Una O'Doherty; Ellen E Paxinos; Anthony S Fauci; H Clifford Lane Journal: Proc Natl Acad Sci U S A Date: 2016-07-18 Impact factor: 11.205
Authors: Shabnum Patel; Elizabeth Chorvinsky; Shuroug Albihani; Conrad Russell Cruz; R Brad Jones; Elizabeth J Shpall; David M Margolis; Richard F Ambinder; Catherine M Bollard Journal: Mol Ther Date: 2018-04-12 Impact factor: 11.454
Authors: Sara Gianella; Jeff Taylor; Timothy R Brown; Andy Kaytes; Cristian L Achim; David J Moore; Susan J Little; Ronald J Ellis; Davey M Smith Journal: AIDS Date: 2017-01-02 Impact factor: 4.177